Neal I. Muni joined Azurity Pharmaceuticals (formerly CutisPharma) as President in July 2014 and was named Chief Executive Officer in May 2015. Neal has served for over 20 years in senior roles across the entire life sciences value chain, including corporate strategy, healthcare mergers and acquisitions, new product planning, pharmaceutical brand launches, clinical development and regulatory affairs.
Prior to joining CutisPharma, Neal was the Executive Director of New Product Planning at Sunovion Pharmaceuticals, a US subsidiary of Sumitomo Dainippon Pharma, leading portfolio strategy and supporting corporate M&A and licensing. Prior to that, Neal was an engagement manager at the healthcare investment bank Leerink Swann, LLC. (Now SVB Leerink). Prior to that, he was a Medical Officer in the Division of Cardiovascular Devices at the FDA. Neal maintained staff appointments with the Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School for 15 years, completing his residency at the Brigham and Women’s Hospital in Internal Medicine. He received his M.D. as well as Master of Science in Public Health, from the Tulane School of Medicine, and a B.A. in Business Economics and B.Sc. in Biochemistry from Brown University.
Azurity Pharmaceuticals™, Inc. was formerly known as CutisPharma®, Inc. Product packaging may reflect either name.
All product imagery is for representation purposes only - not actual labels.
© 2020 Azurity Pharmaceuticals™, Inc. All Rights Reserved.